TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion
Brief Summary: Second trimester abortion can be done surgically or medically. Medical abortion with mifepristone and misopristol is one of the common protocol, but misopristol have high rate side effect. The investigators recent study proved the efficacy of pitocin after mifepristone in second trimester abortion with minimal side effects.

Working hypothesis and aims: To compare misopristol and pitocin after mifepristone preparation in second trimester in seccess rate, interval to abortion, side effects and patient satisfaction.


Options:
A: Arm Label: Misoprostol by physician; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Misoprostol treatment by midwife | Arm Label: Misoprostol by midwife; Type: EXPERIMENTAL; Interventions: Procedure: Misoprostol treatment by midwife | Intervention Type: PROCEDURE; Name: Misoprostol treatment by midwife; Assigned to Arm(s): Misoprostol by midwife, Misoprostol by physician
B: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
D: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion
Brief Summary: Second trimester abortion can be done surgically or medically. Medical abortion with mifepristone and misopristol is one of the common protocol, but misopristol have high rate side effect. The investigators recent study proved the efficacy of pitocin after mifepristone in second trimester abortion with minimal side effects.

Working hypothesis and aims: To compare misopristol and pitocin after mifepristone preparation in second trimester in seccess rate, interval to abortion, side effects and patient satisfaction.


Options:
A: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin
B: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-based Vascular Risk Factor Management for Patients With Clinical Manifest Vascular Disease; a Randomized Controlled Trial
Brief Summary: The objective of the study is to evaluate the efficacy and cost-effectiveness of an internet based vascular risk factor program on top of usual care compared to usual care alone for treatment of vascular risk factors in patients at high risk for new vascular events.


Options:
A: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
B: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
C: Intervention Type: DRUG; Name: Optimal treatment; Assigned to Arm(s): N/A
D: Arm Label: internet based intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: internet based vascular risk factor intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: internet based vascular risk factor intervention; Assigned to Arm(s): internet based intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet-based Vascular Risk Factor Management for Patients With Clinical Manifest Vascular Disease; a Randomized Controlled Trial
Brief Summary: The objective of the study is to evaluate the efficacy and cost-effectiveness of an internet based vascular risk factor program on top of usual care compared to usual care alone for treatment of vascular risk factors in patients at high risk for new vascular events.


Options:
A: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Web Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web intervention | Arm Label: Nurse Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: nurse intervention | Intervention Type: BEHAVIORAL; Name: web intervention; Assigned to Arm(s): Web Intervention | Intervention Type: BEHAVIORAL; Name: nurse intervention; Assigned to Arm(s): Nurse Intervention
C: Arm Label: internet based intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: internet based vascular risk factor intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: internet based vascular risk factor intervention; Assigned to Arm(s): internet based intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Parallel, Time-lagged, Ascending, Multi-centre, Multiple-dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma
Brief Summary: This study will evaluate the effect of FTY720 on the lung function of patients with moderate asthma


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo-fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg, Placebo-fingolimod
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Interferon β-1a 30 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a 30 µg | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Interferon β-1a 30 µg; Assigned to Arm(s): Interferon β-1a 30 µg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery
Brief Summary: This study is designed to determine the minimum effective dose (ED90) of infusions of oxytocin for the prevention of uterine atony / postpartum hemorrhage and the need for additional uterotonics, in low risk parturients presenting for an elective CD.

The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose. Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.


Options:
A: Arm Label: Saline group; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Saline group
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin infusion | Intervention Type: DRUG; Name: Oxytocin infusion; Assigned to Arm(s): A
C: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A
D: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery
Brief Summary: This study is designed to determine the minimum effective dose (ED90) of infusions of oxytocin for the prevention of uterine atony / postpartum hemorrhage and the need for additional uterotonics, in low risk parturients presenting for an elective CD.

The primary outcome measure is the response of effective uterine contraction as either satisfactory or unsatisfactory as determined by the obstetrician blinded to the oxytocin infusion dose. Secondary outcomes will include need for additional uterotonics, calculated intra-operative blood loss and presence of oxytocin related adverse effects.


Options:
A: Arm Label: OCT-group; Type: N/A; Interventions: N/A | Arm Label: None-OCT-group; Type: N/A; Interventions: N/A
B: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3
C: Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 90mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 110mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 90mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 110mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 120mcg
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin infusion | Intervention Type: DRUG; Name: Oxytocin infusion; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT)
Brief Summary: To evaluate the safety and efficacy of chemotherapy with or without enoxaparin. This study is powered to decrease the DVT/ VTE events rate from 10% to 3% with enoxaparin in the experimental arm.

N=540pts, dropout-rate 15%, power 80 %, two sided, significant level 5%


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT)
Brief Summary: To evaluate the safety and efficacy of chemotherapy with or without enoxaparin. This study is powered to decrease the DVT/ VTE events rate from 10% to 3% with enoxaparin in the experimental arm.

N=540pts, dropout-rate 15%, power 80 %, two sided, significant level 5%


Options:
A: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
B: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin + docetaxel + enoxaparin | Intervention Type: DRUG; Name: cisplatin + docetaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin + docetaxel + enoxaparin; Assigned to Arm(s): Arm B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study
Brief Summary: Several studies have shown that bone mineral density (BMD) at the femoral neck decreases with increasing physical handicap (EDSS-score) in MS patients. Possible explanations are less weightbearing exercise or less UV-exposure resulting in reduced vitamin D generation in the skin. Prevention of osteoporosis is a high priority, because treatment of the established disease remains sub-optimal.

We have designed a double-blind randomised controlled trial of two years' duration including 90-100 persons with MS age 18-50 to assess whether supplementation with vitamin D, given as a weekly dose of 20,000 IU cholecalciferol, can prevent bone loss.

The primary objective of this study is to determine changes in BMD over the 2 year study period comparing treatment and placebo groups.

The most important secondary objective is to determine cytokine profiles in blood samples. We will also assess parameters related to vitamin D status and physical performance.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Colecalciferol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Colecalciferol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2
B: Arm Label: High dose vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Low dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): High dose vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Low dose vitamin D
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol, Dietary Supplement: calcium carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium carbonate; Assigned to Arm(s): 1, 2
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Milk, Whey and Casein on Weight Loss and Risk Markers of Metabolic Syndrome in Overweight Children
Brief Summary: Milk contains a vast number of bioactive components that have been suggested to have a positive impact on human health, of special interest is the effects related to metabolic syndrome and obesity but the effect of the individual milk components is not clear. This study examine whether it is beneficial for overweight and obese children to increase the intake of skim milk, or whey or casein in relation to bodyweight and markers of MS.

The participants will be randomized to receive skim milk, whey milk drink, casein milk drink or mineral water for 3 mo. They will be examined at baseline, end of intervention and followed up 3 month later.


Options:
A: Intervention Type: BEHAVIORAL; Name: A lifestyle educational program; Assigned to Arm(s): N/A
B: Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback letters | Arm Label: Feedback plus incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback plus incentives | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback letters; Assigned to Arm(s): Feedback only | Intervention Type: BEHAVIORAL; Name: Feedback plus incentives; Assigned to Arm(s): Feedback plus incentives
C: Arm Label: No calorie beverages; Type: EXPERIMENTAL; Interventions: Behavioral: 2 no calorie beverages per day | Arm Label: Water; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 2 water beverages per day | Intervention Type: BEHAVIORAL; Name: 2 no calorie beverages per day; Assigned to Arm(s): No calorie beverages | Intervention Type: BEHAVIORAL; Name: 2 water beverages per day; Assigned to Arm(s): Water
D: Arm Label: skim milk; Type: EXPERIMENTAL; Interventions: Behavioral: Milk Components and Metabolic syndrome | Arm Label: whey; Type: EXPERIMENTAL; Interventions: Behavioral: Milk Components and Metabolic syndrome | Arm Label: casein; Type: EXPERIMENTAL; Interventions: Behavioral: Milk Components and Metabolic syndrome | Arm Label: water; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Milk Components and Metabolic syndrome | Intervention Type: BEHAVIORAL; Name: Milk Components and Metabolic syndrome; Assigned to Arm(s): casein, skim milk, water, whey

Answer: D